MedTrace Logo

A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

NCT06859203 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2025-03-05

No results posted yet for this study

Summary

The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.

Conditions

  • Biochemical Recurrence of Malignant Neoplasm of Prostate

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Matthias Eiber, MD · Technical University of Munich

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859203 on ClinicalTrials.gov